Top 5 Target	Count

Bcr-Abl T315I(BCR-ABL T315I mutation)	2
PI3Kδ(Phosphatidylinositol 3 kinase delta)	2
EZH2(Histone-lysine N-methyltransferase EZH2)	2
VEGFR2(Vascular endothelial growth factor receptor 2)	1
FLT3(Tyrosine-protein kinase receptor FLT3)	1

Drugs associated with Hefei Institutes of Physical Science

HYML-122

Target

FLT3

Mechanism

FLT3 inhibitors

Active Org.

Tarapeutics Science Inc [+2]

Originator Org.

Hefei Institutes of Physical Science [+1]

Active Indication

Refractory acute myeloid leukemia [+2]

Inactive Indication-

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date-

PI3KD-IN-015

Target

PI3Kδ

Mechanism

PI3Kδ inhibitors

Active Org.

Hefei Heyuan Pharmaceutical Technology Co. Ltd. [+1]

Originator Org.

Hefei Institutes of Physical Science [+1]

Active Indication

B-Cell Malignant Neoplasm

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

CHMFL-ABL-121

Target

Bcr-Abl T315I

Mechanism

Bcr-Abl T315I inhibitors

Active Org.

Hefei Institutes of Physical Science

Originator Org.

Hefei Institutes of Physical Science

Active Indication

BCR-ABL Negative Atypical Chronic Myeloid Leukemia

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with Hefei Institutes of Physical Science

CTR20211957 / RecruitingPhase 2

评价HYML-122片联合阿糖胞苷治疗FLT3突变复发或难治性的急性髓系白血病（AML）患者的有效性和安全性的单臂、开放、多中心临床试验

[Translation] A single-arm, open-label, multicenter clinical trial to evaluate the efficacy and safety of HYML-122 tablets combined with cytarabine in the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations

主要目的：评价HYML-122片联合阿糖胞苷治疗FLT3突变复发或难治性的急性髓系白血病（AML）的有效性，探索最佳给药方案，为Ⅲ期临床试验提供设计依据。次要目的：1)评估HYML-122片在人体内不同给药方案药代动力学特征；2)通过其它次要疗效指标，观察和评价疗效差异；3)观察和评价安全性，包括临床症状体征观察和实验室指标，AE（和SAE）的发生率和严重程度。

[Translation]

Primary objective: To evaluate the efficacy of HYML-122 tablets combined with cytarabine in the treatment of relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutation, explore the optimal dosing regimen, and provide a design basis for Phase III clinical trials. Secondary objectives: 1) To evaluate the pharmacokinetic characteristics of HYML-122 tablets in different dosing regimens in humans; 2) To observe and evaluate the efficacy differences through other secondary efficacy indicators; 3) To observe and evaluate safety, including clinical symptoms and signs observation and laboratory indicators, the incidence and severity of AEs (and SAEs).

Start Date29 Mar 2022

Sponsor / Collaborator

Hefei Institutes of Physical Science

[+1]

CTR20211928 / RecruitingPhase 2

评价HYML-122片单药治疗FLT3突变复发或难治性的急性髓系白血病（AML）患者的有效性和安全性的单臂、开放、多中心临床试验

[Translation] A single-arm, open-label, multicenter clinical trial to evaluate the efficacy and safety of HYML-122 tablets as a monotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations

主要目的：评价HYML-122片单药治疗FLT3突变复发或难治性的急性髓系白血病（AML）的有效性，探索最佳给药方案，为Ⅲ期临床试验提供设计依据。次要目的：1) 评估HYML-122片在人体内不同给药方案药代动力学特征；2) 通过其它次要疗效指标，观察和评价疗效差异； 3) 观察和评价安全性，包括临床症状体征观察和实验室指标，AE（和SAE）的发生率和严重程度

[Translation]

Primary purpose: To evaluate the efficacy of HYML-122 tablets as a single agent in the treatment of relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutation, explore the best dosing regimen, and provide a design basis for Phase III clinical trials. Secondary objectives: 1) To evaluate the pharmacokinetic characteristics of HYML-122 tablets in different dosing regimens in humans; 2) To observe and evaluate the efficacy differences through other secondary efficacy indicators; 3) To observe and evaluate safety, including clinical symptoms and signs observation and laboratory indicators, the incidence and severity of AEs (and SAEs).

Start Date26 Sep 2021

Sponsor / Collaborator

Hefei Institutes of Physical Science

[+1]

ISRCTN12308193 / RecruitingNot Applicable

Non-invasive and accurate diagnosis of type 2 diabetes using urinary acetone: a prospective multicenter study

Start Date20 Apr 2021

Sponsor / Collaborator

Hefei Institutes of Physical Science

100 Clinical Results associated with Hefei Institutes of Physical Science

0 Patents (Medical) associated with Hefei Institutes of Physical Science

3,997

Literatures (Medical) associated with Hefei Institutes of Physical Science

01 Apr 2025·Journal of Environmental Sciences

Long-term spatiotemporal variations of ammonia in the Yangtze River Delta region of China and its driving factors

Article

Author: Liu, Cheng ; Zhang, Chengxin ; Li, Qihua ; Liu, Ting ; Xue, Jingkai ; Xing, Chengzhi ; Hu, Qihou ; Zhu, Yizhi ; Wang, Shanshan

This study focuses on the spatiotemporal distribution, urban-rural variations, and driving factors of ammonia Vertical Column Densities (VCDs) in China's Yangtze River Delta region (YRD) from 2008 to 2020. Utilizing data from the Infrared Atmospheric Sounding Interferometer (IASI), Generalized Additive Models (GAM), and the GEOS-Chem chemical transport model, we observed a significant increase of NH₃ VCDs in the YRD between 2014 and 2020. The spatial distribution analysis revealed higher NH₃ concentrations in the northern part of the YRD region, primarily due to lower precipitation, alkaline soil, and intensive agricultural activities. NH₃ VCDs in the YRD region increased significantly (65.18%) from 2008 to 2020. The highest growth rate occurs in the summer, with an annual average growth rate of 7.2% during the period from 2014 to 2020. Agricultural emissions dominated NH₃ VCDs during spring and summer, with high concentrations primarily located in the agricultural areas adjacent to densely populated urban zones. Regions within several large urban areas have been discovered to exhibit relatively stable variations in NH₃ VCDs. The rise in NH₃ VCDs within the YRD region was primarily driven by the reduction of acidic gases like SO₂, as emphasized by GAM modeling and sensitivity tests using the GEOS-Chem model. The concentration changes of acidic gases contribute to over 80% of the interannual variations in NH₃ VCDs. This emphasizes the crucial role of environmental policies targeting the reduction of these acidic gases. Effective emission control is urgent to mitigate environmental hazards and secondary particulate matter, especially in the northern YRD.

01 Jan 2025·Talanta

A novel prognosis evaluation indicator of patients with sepsis created by integrating six microfluidic-based neutrophil chemotactic migration parameters

Review

Author: Yang, Ke ; Pu, Xuexue ; Cui, Junsheng ; Zhao, Jun ; Zhu, Ling ; Shao, Min ; Fang, Xiao ; Xu, Yuanyuan ; Yang, Xiao ; Liu, Yong ; Deng, Guoqing

Impaired neutrophil migration in sepsis is associated with a poor prognosis. The potential of utilizing neutrophil chemotaxis to assess immune function, disease severity, and patient prognosis in sepsis remains underexplored. This study employed an innovative approach by integrating a multi-tip pipette with a Six-Unit microfluidic chip (SU⁶-chip) to establish gradients in six microchannels, thereby analyzing neutrophil chemotaxis in sepsis patients. We compared chemotactic parameters between healthy controls (N_H = 20) and sepsis patients (N_S1 = 25), observing significant differences in gradient perception time (GP), migration distance (MD), peak velocity (V_max), chemotactic index (CI), reverse migration rate (RM), and stop migration number (SM). A novel composite indicator, the Sepsis Neutrophil Migration Evaluation (SNME) index, was developed by integrating these six chemotactic migration parameters. The SNME index and individual chemotaxis parameters showed significant correlations with the Sequential Organ Failure Assessment (SOFA) score, Acute Physiology and Chronic Health Evaluation (APACHE II) score, hypersensitivity C-reactive protein (hs-CRP), and heparin-binding protein (HBP). Moreover, the SNME index demonstrated potential for monitoring sepsis progression, with ROC analysis confirming its predictive accuracy (area under the curve [AUC] = 0.895, cutoff value = 31.5, specificity = 86.73 %, sensitivity = 86.71 %), outperforming individual neutrophil chemotactic parameters. In conclusion, the SNME index represents a promising new tool for adjunctive diagnosis and prognosis assessment in patients with sepsis.

01 Jan 2025·Talanta

A study on the determination of the metabolites of 2,4,6-Trinitrotoluene using a dual-drift tube ion mobility spectrometer

Article

Author: Chu, Yannan ; Zhang, Xu ; Kong, Lingwen ; Liu, Yawei ; Song, Yu ; Shen, Chengyin ; Li, Wanjun ; Huang, Chaoqun ; Luo, Yuanjiang ; Xia, Lei

2,4,6-Trinitrotoluene (TNT) and its four metabolites, namely 2-ADNT, 4-ADNT, 2,4-DANT, and 2,6-DANT, are highly toxic substances. These metabolites also serve as biomarkers for assessing the health of individuals exposed to TNT. In this study, a homemade DDT-IMS apparatus was utilized to detect these metabolites. Under negative detection mode, the drift times of 2-ADNT and 4-ADNT showed subtle shifts within a drift tube temperature range of 100 °C-120 °C, aiding in their differentiation. In positive detection mode for 2,4-DANT and 2,6-DANT, significant variations were observed in both the number and drift time of their positive product ions across a drift tube temperature range of 80 °C-120 °C. Consequently, optimal analytical performance for these metabolites was achieved at approximately 100 °C. Evaluation of the instrumental response during the measurement of the four metabolites in both positive and negative modes revealed that negative detection mode offered greater advantages of detecting these compounds. The working ranges for measuring the four metabolites spanned two orders of magnitude, with detection limits for each metabolite nearly below 1 ng. Notably, clear identification of the signals for these metabolites was achieved even when samples were mixed in urine, highlighting the ability of the DDT-IMS in detecting TNT metabolites. The developed DDT-IMS detection method has significant potential for enhancing environmental risk assessment and biological hazard evaluation, particularly in relation to human exposure to TNT.

100 Deals associated with Hefei Institutes of Physical Science

100 Translational Medicine associated with Hefei Institutes of Physical Science

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Phase 2 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

HYML-122 ( FLT3 )	FLT3 positive Acute Myeloid Leukemia More	Phase 2
CHMFL-PI4K-127 ( PfPI4K )	Malaria More	Preclinical
CHMFL-KIT-033 ( c-Kit )	Gastrointestinal Stromal Tumors More	Preclinical
IHMT-EZH-2-115 ( EZH2 )	B-Cell Lymphoma More	Preclinical
PI3KD-IN-015 ( PI3Kδ )	B-Cell Malignant Neoplasm More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis